Actuate Therapeutics
ACTU
64 hedge funds and large institutions have $20.7M invested in Actuate Therapeutics in 2026 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 20 reducing their positions, and 14 closing their positions.
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
5% more funds holding
Funds holding: 61 → 64 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.97% less ownership
Funds ownership: 58.45% → 56.48% (-2%)
10% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 20
46% less capital invested
Capital invested by funds: $38M → $20.7M (-$17.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$233K |
| 2 |
Millennium Management
New York
|
+$224K |
| 3 |
Jane Street
New York
|
+$90.7K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$84.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$65.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$781K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$310K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$268K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$178K |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
-$152K |
ACTU Hedge Fund Activity: Q2 2026 in Review
64 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Actuate Therapeutics (ACTU) for Q2 2026, worth a combined $20.7M — down 46% from $38M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ACTU positions and 14 closed out — a net gain of 4 holders — while 18 added to existing stakes and 20 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $233K. The largest seller was BlackRock, cutting an estimated $781K.
- 64 institutional investors held Actuate Therapeutics (ACTU) as of Q2 2026, up from 61 in Q1 2026.
- Funds reported $20.7M of Actuate Therapeutics stock for Q2 2026, down 46% quarter-over-quarter.
- 18 funds opened new Actuate Therapeutics positions in Q2 2026 and 14 closed out, a net change of +4 holders.
- The largest Actuate Therapeutics buyer in Q2 2026 was AQR Capital Management, an estimated $233K added.
- The largest Actuate Therapeutics seller in Q2 2026 was BlackRock, an estimated $781K sold.
Based on aggregated 13F filings for Q2 2026.